Daily News header

Does an Aspirin A Day Keep Colon Cancer Away?

By  

Most people already know that a dose of "baby" aspirin taken each day is beneficial for many older people's health because it reduces the chance of a heart attack and some kinds of strokes but a new study out of the UK by Professor Peter Rothwell, John Radcliffe Hospital, Oxford, and University of Oxford, UK, and colleagues shows benefits related to colorectal cancer.

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61543-7/abstract

Previous studies showed that high doses (>500mg) day were beneficial but daily high doses can be dangerous because aspirin can cause stomach bleeding and other problems.

The new study indicates that even at low doses people over 40 years-of-age will see a 25% reduction in colon cancer if they take a baby aspirin every day.

Long term use also reduces mortality (death rate) due to proximal colon cancer.

"Aspirin taken for several years at doses of at least 75 mg daily reduced long-term incidence and mortality due to colorectal cancer. Benefit was greatest for cancers of the proximal colon, which are not otherwise prevented effectively by screening with sigmoidoscopy or colonoscopy."

There is a discussion on the Lancet Facebook page.

John McCormick is a reporter, /science/medical columnist and finance and social commentator, with 17,000+ bylined stories. Contact John through NewsBlaze.

  Please leave a comment here     If it does not display within 10 seconds, please refresh the page

Related Health News News

Sleep related laryngospasm a rare condition causes people to jump out of bed from a deep sleep, choking and unable to breathe for several seconds.
Consumption of emulsifiers used in many processed foods such as ice cream is related to Inflammatory Bowel Disease and other conditions.
Attorney General Healey has opposed the deal between Coakley and Partners and threatened legal action to stop the acquisition from going through.
The Global Alliance for TB Drug Development (TB Alliance) announced on February 19, 2015 the start of the first human study of a new TB drug candidate TBA-354-the first new potential TB drug to begin a Phase 1 clinical study in 6 years since 2009.
Sometimes there is a waste in health and medical research, says Dr Hans Lund, Chair of EBRNetwork Steering Group and a senior researcher at University of Southern Denmark.
Before World Cancer Day, an acquaintance succumbed to this disease within 10 months of diagnosis, and became part of the world statistics of someone dying of lung cancer every 30 seconds.

 

NewsBlaze Writers Of The Month


Popular Stories This Month

newsletter logo

landing page ad

NewsBlaze
Copyright © 2004-2014 NewsBlaze Pty. Ltd.
Use of this website is subject to our Terms of Service and Privacy Policy  | DMCA Notice               Press Room   |    Visit NewsBlaze Mobile Site